N2OFF (NITO) said Wednesday that it signed a definitive deal to acquire the biotech company MitoCareX Bio from owners Alon Silberman, Ciro Leonardo Pierri and SciSparc (SPRC)
Under the terms, N2OFF will purchase 4,961 MitoCareX shares from SciSparc for $700,000 and exchange additional shares with the all sellers for stock totaling 40% of its outstanding share capital.
N2OFF said the sellers will also be entitled to 30% of its financing proceeds, up to a maximum of $1.6 million, over five years and milestone-based issuances of up to 25% of its common shares.
MitoCareX will become a subsidiary of N2OFF after closing of the transaction, which remains subject to approval by N2OFF shareholders, the company said.
N2OFF shares were down more than 15% in recent trading Wednesday.
Price: 0.52, Change: -0.05, Percent Change: -9.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.